{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T02:17:59Z","timestamp":1773886679382,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["Quadruple Aim and Equity Catalyst Grant (QAE-180974)"],"award-info":[{"award-number":["Quadruple Aim and Equity Catalyst Grant (QAE-180974)"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["Quadruple Aim and Equity Catalyst Grant (QAE-180974)"],"award-info":[{"award-number":["Quadruple Aim and Equity Catalyst Grant (QAE-180974)"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["Quadruple Aim and Equity Catalyst Grant (QAE-180974)"],"award-info":[{"award-number":["Quadruple Aim and Equity Catalyst Grant (QAE-180974)"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Health Canada, Substance Use and Addiction Program","award":["1920-HQ-000031"],"award-info":[{"award-number":["1920-HQ-000031"]}]},{"name":"Health Canada, Substance Use and Addiction Program","award":["1920-HQ-000031"],"award-info":[{"award-number":["1920-HQ-000031"]}]},{"name":"Health Canada, Substance Use and Addiction Program","award":["1920-HQ-000031"],"award-info":[{"award-number":["1920-HQ-000031"]}]},{"name":"Health Canada, Substance Use and Addiction Program","award":["1920-HQ-000031"],"award-info":[{"award-number":["1920-HQ-000031"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Federal deregulation of opioid agonist therapies are an attractive policy option to improve access to opioid use disorder care and achieve widespread beneficial impacts on growing opioid-related harms. There have been few evaluations of such policy interventions and understanding effects can help policy planning across jurisdictions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Using health administrative data from eight of ten Canadian provinces, this study evaluated the impacts of Health Canada\u2019s decision in May 2018 to rescind the requirement for Canadian health professionals to obtain an exemption from the <jats:italic>Canadian Drugs and Substance Act<\/jats:italic> to prescribe methadone for opioid use disorder. Over the study period of June 2017 to May 2019, we used descriptive statistics to capture overall trends in the number of agonist therapy prescribers across provinces and we used interrupted time series analysis to determine the effect of this decision on the trajectories of the agonist therapy prescribing workforces.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>There were important baseline differences in the numbers of agonist therapy prescribers. The province with the highest concentration of prescribers had 7.5 more prescribers per 100,000 residents compared to the province with the lowest. All provinces showed encouraging growth in the number of prescribers through the study period, though the fastest growing province grew 4.5 times more than the slowest. Interrupted time series analyses demonstrated a range of effects of the federal policy intervention on the provinces, from clearly positive changes to possibly negative effects.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Federal drug regulation policy change interacted in complex ways with provincial health professional regulation and healthcare delivery, kaleidoscoping the effects of federal policy intervention. For Canada and other health systems such as the US, federal policy must account for significant subnational variation in OUD epidemiology and drug regulation to maximize intended beneficial effects and mitigate the risks of negative effects.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12913-024-11281-9","type":"journal-article","created":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T12:03:58Z","timestamp":1722859438000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Federal opioid agonist therapy policy: interrupted time series analysis of the impact of the methadone exemption removal across eight provinces in Canada"],"prefix":"10.1186","volume":"24","author":[{"given":"Abhimanyu","family":"Sud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chloe","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arani","family":"Sivakumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross","family":"Upshur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahim","family":"Moineddin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kellia","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,5]]},"reference":[{"key":"11281_CR1","unstructured":"National Academies of Sciences, Engineering, and, Medicine H, Division M, Board on Health Sciences Policy. et al. Medications for opioid Use Disorder Save lives. National Academies; 2019. p. 174."},{"issue":"1","key":"11281_CR2","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13011-022-00463-5","volume":"17","author":"EM Pijl","year":"2022","unstructured":"Pijl EM, Alraja A, Duff E, et al. Barriers and facilitators to opioid agonist therapy in rural and remote communities in Canada: an integrative review. Subst Abuse Treat Prev Policy. 2022;17(1):62.","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"11281_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.drugpo.2019.01.015","volume":"66","author":"T Antoniou","year":"2019","unstructured":"Antoniou T, Ala-Leppilampi K, Shearer D, et al. Like being put on an ice floe and shoved away: a qualitative study of the impacts of opioid-related policy changes on people who take opioids. Int J Drug Policy. 2019;66:15\u201322.","journal-title":"Int J Drug Policy"},{"issue":"Suppl 1","key":"11281_CR4","first-page":"S17","volume":"13","author":"M Auriacombe","year":"2004","unstructured":"Auriacombe M, Fats\u00e9as M, Dubernet J, et al. French field experience with buprenorphine. Am J Addict. 2004;13(Suppl 1):S17\u201328.","journal-title":"Am J Addict"},{"key":"11281_CR5","doi-asserted-by":"crossref","unstructured":"Sud A, Chiu K, Friedman J et al. Buprenorphine deregulation as an opioid crisis policy response - a comparative analysis between France and the United States. ijdp. 2023.","DOI":"10.1016\/j.drugpo.2023.104161"},{"key":"11281_CR6","unstructured":"Substance Abuse and Mental Health Service Administration. Waiver elimination (MAT act) [Internet]. 2023 [cited 2023 Jul 12]. https:\/\/www.samhsa.gov\/medications-substance-use-disorders\/waiver-elimination-mat-act."},{"key":"11281_CR7","unstructured":"White House hosts event. to Mark removal of barriers to addiction treatment [Internet]. The White House. 2023 [cited 2023 Feb 6]. https:\/\/www.whitehouse.gov\/ondcp\/briefing-room\/2023\/01\/25\/white-house-hosts-event-to-mark-removal-of-barriers-to-addiction-treatment\/."},{"key":"11281_CR8","doi-asserted-by":"publisher","first-page":"108032","DOI":"10.1016\/j.jsat.2020.108032","volume":"115","author":"SG Auty","year":"2020","unstructured":"Auty SG, Stein MD, Walley AY, et al. Buprenorphine waiver uptake among nurse practitioners and physician assistants: the role of existing waivered prescriber supply. J Subst Abuse Treat. 2020;115:108032.","journal-title":"J Subst Abuse Treat"},{"issue":"19","key":"11281_CR9","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMsa2212412","volume":"388","author":"ML Barnett","year":"2023","unstructured":"Barnett ML, Meara E, Lewinson T, et al. Racial inequality in receipt of medications for opioid Use Disorder. N Engl J Med. 2023;388(19):1779\u201389.","journal-title":"N Engl J Med"},{"issue":"4","key":"11281_CR10","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1080\/08897077.2018.1449166","volume":"39","author":"BD Stein","year":"2018","unstructured":"Stein BD, Dick AW, Sorbero M, et al. A population-based examination of trends and disparities in medication treatment for opioid use disorders among Medicaid enrollees. Subst Abus. 2018;39(4):419\u201325.","journal-title":"Subst Abus"},{"issue":"9","key":"11281_CR11","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/jamapsychiatry.2019.0876","volume":"76","author":"PA Lagisetty","year":"2019","unstructured":"Lagisetty PA, Ross R, Bohnert A, et al. Buprenorphine Treatment divide by Race\/Ethnicity and payment. JAMA Psychiatry. 2019;76(9):979\u201381.","journal-title":"JAMA Psychiatry"},{"key":"11281_CR12","unstructured":"Last year prevalence of high-. risk opioid use among adults in Europe [Internet]. [cited 2023 Jul 12]. https:\/\/www.emcdda.europa.eu\/media-library\/last-year-prevalence-high-risk-opioid-use-among-adults-europe_en."},{"key":"11281_CR13","unstructured":"Digital Communications Division (DCD). Opioid facts and statistics [Internet]. Hhs.gov. US Department of Health and Human Services; 2022 [cited 2023 Jul 12]. https:\/\/www.hhs.gov\/opioids\/statistics\/index.html."},{"key":"11281_CR14","unstructured":"Opioid- and stimulant. -related harms \u2014 Canada.ca [Internet]. [cited 2023 Jul 12]. https:\/\/health-infobase.canada.ca\/substance-related-harms\/opioids-stimulants\/."},{"key":"11281_CR15","unstructured":"Health Canada. Methadone Program [Internet]. 2017 [cited 2023 Jul 10]. https:\/\/www.canada.ca\/en\/health-canada\/services\/health-concerns\/controlled-substances-precursor-chemicals\/exemptions\/methadone-program.html."},{"key":"11281_CR16","unstructured":"Government of Canada. Canada S. Population - Canada at a Glance, 2019 [Internet]. 2018 [cited 2023 Jul 14]. https:\/\/www150.statcan.gc.ca\/n1\/pub\/12-581-x\/2019001\/pop-eng.htm."},{"key":"11281_CR17","unstructured":"National Prescription Drug Utilization. Information System metadata [Internet]. [cited 2023 Jul 14]. https:\/\/www.cihi.ca\/en\/national-prescription-drug-utilization-information-system-metadata."},{"issue":"2","key":"11281_CR18","first-page":"1135","volume":"4","author":"MJ Schull","year":"2020","unstructured":"Schull MJ, Azimaee M, Marra M, et al. ICES: data, Discovery, Better Health. Int J Popul Data Sci. 2020;4(2):1135.","journal-title":"Int J Popul Data Sci"},{"key":"11281_CR19","unstructured":"Prescription monitoring program. About NSPMP [Internet]. [cited 2023 Sep 6]. https:\/\/www.nspmp.ca\/about-nspmp."},{"issue":"3","key":"11281_CR20","first-page":"49","volume":"19","author":"C Campbell","year":"2024","unstructured":"Campbell C, Chiu K, Sud A. Methadone prescribing regulation for opioid use disorder in Canada: evidence for an east\u2013west policy divide. Healthc Policy | Polit Sant\u00e9. 2024;19(3):49\u201361.","journal-title":"Healthc Policy | Polit Sant\u00e9"},{"key":"11281_CR21","unstructured":"Products - vital. statistics rapid release - provisional drug overdose data [Internet]. 2023 [cited 2023 Nov 3]. https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm."},{"issue":"2","key":"11281_CR22","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1177\/1077558718793070","volume":"77","author":"CHA Andrilla","year":"2020","unstructured":"Andrilla CHA, Patterson DG, Moore TE, et al. Projected Contributions of Nurse Practitioners and Physicians Assistant to Buprenorphine Treatment Services for Opioid Use Disorder in Rural Areas. Med Care Res Rev. 2020;77(2):208\u201316.","journal-title":"Med Care Res Rev"},{"key":"11281_CR23","unstructured":"New Fee Codes for the Clinical Management of Opioid Use Disorder [Internet]. British Columbia Centre on Substance Use; 2018 Aug [cited 2023 Apr 15]. https:\/\/divisionsbc.ca\/sites\/default\/files\/51936\/New-Fee-Codes-DYK_21Aug2018.pdf."},{"key":"11281_CR24","unstructured":"Methadone Maintenance Treatment Policy Rescinded [Internet]. eDialogue. [cited 2023 Oct 23]. https:\/\/dialogue.cpso.on.ca\/2021\/03\/methadone-maintenance-treatment-policy-rescinded\/."},{"key":"11281_CR25","unstructured":"Nova Scotia College of Nursing. Nurse Practitioners Prescribing Methadone Regulatory Guideline. Bedford, Nova Scotia: Nova Scotia College of Nursing; 2018 May."},{"key":"11281_CR26","unstructured":"Number of physicians. and nurses per 10,000 population by health region, 2021 [Internet]. [cited 2023 Nov 3]. https:\/\/www.cihi.ca\/en\/number-of-physicians-and-nurses-per-10000-population-by-health-region-2021."},{"key":"11281_CR27","unstructured":"Nurse Practitioners now. able to prescribe methadone [Internet]. [cited 2023 Oct 23]. https:\/\/abpharmacy.ca\/articles\/nurse-practitioners-now-able-prescribe-methadone."},{"key":"11281_CR28","unstructured":"College of Registered Nurses of Manitoba. Registered nurse (nurse practitioner) prescribing controlled drugs and substances. 2002 Jun. Report No.: AA-22."},{"key":"11281_CR29","unstructured":"Manitoba opioid agonist therapy recommended practice. manual - the college of physicians & surgeons of Manitoba [Internet]. [cited 2024 Jun 5]. https:\/\/www.cpsm.mb.ca\/prescribing-practices-program\/manitoba-buprenorphine-naloxone-recommended-practice-manual."},{"issue":"5","key":"11281_CR30","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/s11920-007-0046-2","volume":"9","author":"M Fatseas","year":"2007","unstructured":"Fatseas M, Auriacombe M. Why buprenorphine is so successful in treating opiate addiction in France. Curr Psychiatry Rep. 2007;9(5):358\u201364.","journal-title":"Curr Psychiatry Rep"},{"issue":"6","key":"11281_CR31","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1159\/000506630","volume":"26","author":"J Dupouy","year":"2020","unstructured":"Dupouy J, Maumus-Robert S, Mansiaux Y, et al. Primary care of opioid use disorder: the end of the French model? Eur Addict Res. 2020;26(6):346\u201354.","journal-title":"Eur Addict Res"},{"key":"11281_CR32","unstructured":"France [Internet]. 2020 [cited 2023 Sep 27]. https:\/\/www.commonwealthfund.org\/international-health-policy-center\/countries\/france."},{"key":"11281_CR33","doi-asserted-by":"publisher","first-page":"104141","DOI":"10.1016\/j.drugpo.2023.104141","volume":"119","author":"A Conway","year":"2023","unstructured":"Conway A, Krawczyk N, McGaffey F, et al. Typology of laws restricting access to methadone treatment in the United States: a latent class analysis. Int J Drug Policy. 2023;119:104141.","journal-title":"Int J Drug Policy"},{"key":"11281_CR34","doi-asserted-by":"crossref","unstructured":"Chloe Campbell KCAAS. Methadone Prescribing Regulation for Opioid Use Disorder in Canada: Evidence for an East\/West Policy Divide. Healthc Policy [Internet]. 2023;19(3 Pre-release). https:\/\/www.longwoods.com\/product\/27228.","DOI":"10.12927\/hcpol.2023.27228"},{"key":"11281_CR35","doi-asserted-by":"publisher","first-page":"112642","DOI":"10.1016\/j.socscimed.2019.112642","volume":"244","author":"F Webster","year":"2020","unstructured":"Webster F, Rice K, Sud A. A critical content analysis of media reporting on opioids: the social construction of an epidemic. Soc Sci Med. 2020;244:112642.","journal-title":"Soc Sci Med"},{"key":"11281_CR36","unstructured":"Power BI. report [Internet]. [cited 2023 Sep 27]. https:\/\/app.powerbi.com\/view?r=eyJrIjoiYTdiOGJlMmYtZTBmMC00N2FlLWI2YmYtMDIzOTY5NzkwODViIiwidCI6IjZmZGI1MjAwLTNkMGQtNGE4YS1iMDM2LWQzNjg1ZTM1OWFkYyJ9."},{"key":"11281_CR37","unstructured":"Iacono A, Munro C, Nunez E, Gomes T, Murray R, Kolla G, Leece P, Kitchen S, Campbell T, Besharah J, Cahill T, Garg R et al. 2022; https:\/\/www.allianceon.org\/sites\/default\/files\/opioid-related-toxicity-deaths-and-healthcare-use-report.pdf."},{"issue":"1","key":"11281_CR38","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13011-019-0220-7","volume":"14","author":"S Taha","year":"2019","unstructured":"Taha S, Maloney-Hall B, Buxton J. Lessons learned from the opioid crisis across the pillars of the Canadian drugs and substances strategy. Subst Abuse Treat Prev Policy. 2019;14(1):32.","journal-title":"Subst Abuse Treat Prev Policy"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-024-11281-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-024-11281-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-024-11281-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T12:09:18Z","timestamp":1722859758000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-024-11281-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,5]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["11281"],"URL":"https:\/\/doi.org\/10.1186\/s12913-024-11281-9","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,5]]},"assertion":[{"value":"5 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study relied exclusively on secondary use of anonymous information which did not generate identifiable information and so was exempt from ethics board approval as per the University of Toronto Research Ethics Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"893"}}